

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司 *
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

INSIDE INFORMATION
BUSINESS UPDATE OF THE NON-CELL THERAPY BUSINESS
FOR THE SIX MONTHS ENDED 30 JUNE 2023

This announcement is made by GenScript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to update the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company on the Company’s performance of the non-cell therapy business for the six months ended 30 June 2023 (the “**Reporting Period**”) based on the preliminary assessment of the latest unaudited management accounts of the Group and the information currently available.

- (1) Life-science services and products segment: during the Reporting Period, the revenue from the segment is expected to range from approximately US\$197.1 million to US\$205.9 million, as compared to approximately US\$176.0 million for the corresponding period in 2022, representing an increase from 12.0% to 17.0%.
- (2) Biologics development services segment: during the Reporting Period, the revenue from the segment is expected to range from approximately US\$62.7 million to US\$65.8 million, as compared to approximately US\$62.7 million for the corresponding period in 2022, representing an increase from 0% to 5.0%.
- (3) Industrial synthetic biology products segment: during the Reporting Period, the revenue from the segment is expected to range from approximately US\$17.8 million to US\$18.5 million, as compared to approximately US\$16.8 million for the corresponding period in 2022, representing an increase from 6.0% to 10.0%.

The purpose of this announcement is to keep the Shareholders and potential investors of the Company informed of the update of the non-cell therapy business of the Group.

The information contained in this announcement can only be treated as a preliminary assessment by the Board based on the latest unaudited management accounts of the Group and the information currently available (excluding the segment revenue from the cell therapy business), which are subject to finalisation and other potential adjustments, and is not based on any figures or information that has been audited, confirmed or reviewed by the auditor of the Company. Shareholders and potential investors of the Company are advised to read the interim results announcement of the Company for the Reporting Period (including the interim results of the Company's cell therapy business), which is expected to be published before the end of August 2023.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 13 July 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai

** For identification purposes only*